Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6782MR)

This product GTTS-WQ6782MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6782MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13840MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ13985MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ5108MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ5177MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ7108MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ3720MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ15324MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW